{"entity":{"id":"nct06530251","kind":"trial","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","aka":[],"tldr":"A phase 1/2 trial of Ivonescimab, Cadonilimab, Sintilimab in hepatocellular carcinoma, run by Akeso, now recruiting.","summary":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06530251 by Akeso, with 280 participants planned, started 2024-09-24 and due to reach its primary completion in 2026-06. Interventions recorded: AK112, Cadonilimab, AK127, AK130, Sintilimab Injection. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06530251","url":"https://clinicaltrials.gov/study/NCT06530251"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab","cadonilimab","sintilimab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06530251","phase":"1/2","setting":"A Phase Ib/II Study of AK112 in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)","sponsor":"Akeso","enrolled":280,"outcomes":[]},"route":"/trials/nct06530251/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}